Aclarion Announces First Commercial Agreement with Scripps Health
Rhea-AI Summary
Aclarion (Nasdaq: ACON) has secured its first commercial agreement with Scripps Health in San Diego, expanding access to its Nociscan technology. The agreement brings the diagnostic solution to Southern California's largest healthcare system, serving over 3.2M people in the San Diego Metro area.
Nociscan, which uses MR Spectroscopy and AI to identify chronic low back pain sources, will be available at Scripps Green Hospital. Dr. Robert Eastlack, Orthopedic Surgeon at Scripps Health, emphasized the technology's value in providing additional diagnostic information for patients previously referred to Beverly Hills for the procedure.
Scripps Health operates five hospitals and 19 outpatient facilities, treating 500,000 patients annually through 2,600 affiliated physicians. The system will implement Nociscan both in clinical practice and research trials, supporting their mission to advance spine care.
Positive
- First commercial agreement with major healthcare system Scripps Health
- Access to 3.2M potential patients in San Diego Metro area
- Integration into both clinical practice and research trials
- Expansion into Southern California market
Negative
- None.
Insights
Aclarion's commercial agreement with Scripps Health represents a strategic market expansion for their Nociscan technology. This diagnostic platform addresses a substantial clinical need in the chronic low back pain market, which affects approximately
What's particularly noteworthy is that patients were previously being referred from San Diego to Beverly Hills specifically for Nociscan procedures, demonstrating existing physician demand for this diagnostic capability. This agreement eliminates that geographic barrier by making the technology directly available at Scripps Green Hospital.
The endorsement from Dr. Eastlack, who has published over 100 peer-reviewed articles, provides significant clinical validation. His statement that Nociscan provides "additional information" that has been "valuable to me and my patients" speaks to the technology's clinical utility in enhancing diagnostic accuracy for chronic low back pain.
Scripps Health serves 500,000 patients annually through its network of five hospitals and 19 outpatient facilities, with access to 2,600 affiliated physicians. This partnership immediately expands Aclarion's potential user base within a major metropolitan healthcare system serving 3.2 million people.
The agreement also enables integration of Nociscan into ongoing research trials at Scripps, potentially generating additional clinical evidence supporting the technology's utility in spine care pathways.
This commercial agreement marks Aclarion's entry into the Southern California healthcare market through a partnership with the region's dominant healthcare provider. For a company with a
The structure of this deal aligns with Aclarion's SaaS (Software as a Service) business model for Nociscan, potentially establishing a recurring revenue stream from the Scripps Health network. While financial terms remain undisclosed, the agreement provides Aclarion access to Scripps' extensive patient population and physician network.
Particularly valuable is that this agreement incorporates both clinical use and research applications, creating two parallel avenues for technology adoption. The research component may generate additional validation data to support future expansion opportunities.
Dr. Eastlack's previous practice of referring patients to Beverly Hills for Nociscan suggests an established clinical demand that can now be served locally. This existing champion within Scripps' system could accelerate physician adoption across the network.
This agreement demonstrates commercial validation for Aclarion's technology in addressing the diagnostic challenges of chronic low back pain. As their first announced commercial agreement, this represents a important proof point for Aclarion's go-to-market strategy and could serve as a template for additional healthcare system partnerships across other metropolitan markets.
Agreement expands access to Nociscan technology for leading spine physicians and more than 3.2M people in the greater San Diego Metro area
Nociscan leverages MR Spectroscopy (MRS) and Augmented Intelligence (AI) to Identify Sources of Chronic Low Back Pain
BROOMFIELD, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Scripps Health in San Diego, CA. The agreement brings Nociscan to southern California and the leading spine physicians of Scripps Green and Scripps Health, the largest healthcare system in the San Diego area.
“Each year at Scripps, we evaluate a large, growing number of patients suffering from chronic low back pain,” said Robert Eastlack, MD, Orthopedic Surgeon, Scripps Health. “I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. Over the last few years, I have referred numerous patients to Beverly Hills for Nociscan. The additional information unique from Nociscan has been valuable to me and my patients. Having Nociscan available at Scripps Green will greatly expand access to my colleagues and our patients in important ways.”
Scripps Health is a nonprofit health care system that includes five hospitals and 19 outpatient facilities and treats a half-million patients annually through 2,600 affiliated physicians. The system also includes clinical research and medical education programs.
“Dr. Eastlack is a leader within Scripps, as well as the San Diego Spine Foundation and the International Spine Study Group, having published over 100 peer-reviewed articles and contributing to nearly a dozen textbooks,” said Ryan Bond, Chief Strategy Officer of Aclarion. “We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California. Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain.
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities of Aclarion, Inc. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
What is the significance of Aclarion's (ACON) commercial agreement with Scripps Health?
How many patients will potentially have access to Nociscan through the Scripps Health agreement?
What technology does Aclarion's Nociscan use to identify chronic low back pain?
How will Scripps Health implement Aclarion's Nociscan technology?
